EGFR and non-small cell lung carcinoma: Among 85 advanced NSCLC patients with EGFR mutations who received ICIs, the ORR, median PFS, and OS were 21.2%, 7.2 months [95% confidence interval (CI): 5.6–8.9, Fig. 1A] and 27.4 months (95% CI:19.2–35.6, Fig. 1B), respectively.